12/19
05:58 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.
12/19
05:58 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.
12/18
09:12 am
rna
Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI
Low
Report
Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI
12/18
09:12 am
rna
Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI
Low
Report
Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI
11/11
08:08 am
rna
Avidity Biosciences (NASDAQ:RNA) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $72.00 price target on the stock.
Low
Report
Avidity Biosciences (NASDAQ:RNA) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $72.00 price target on the stock.
11/11
07:58 am
rna
Rating for RNA
Low
Report
Rating for RNA
10/30
10:48 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Wolfe Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Wolfe Research from a "strong-buy" rating to a "hold" rating.
10/30
10:48 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Wolfe Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Wolfe Research from a "strong-buy" rating to a "hold" rating.
10/29
08:02 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
10/29
08:02 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
10/29
08:02 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Chardan Capital from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Chardan Capital from a "strong-buy" rating to a "hold" rating.
10/28
07:14 am
rna
Rating for RNA
Low
Report
Rating for RNA
10/28
06:29 am
rna
Avidity Biosciences downgraded to Neutral from Buy at Citi
Low
Report
Avidity Biosciences downgraded to Neutral from Buy at Citi
10/28
06:13 am
rna
Rating for RNA
Low
Report
Rating for RNA
10/28
06:13 am
rna
Rating for RNA
Low
Report
Rating for RNA
10/28
04:21 am
rna
Avidity Biosciences downgraded to Neutral from Buy at Chardan
Low
Report
Avidity Biosciences downgraded to Neutral from Buy at Chardan
10/27
06:30 pm
rna
Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital
Low
Report
Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital
10/27
06:30 pm
rna
Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital
Low
Report
Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital
10/27
03:04 pm
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating.
10/27
12:40 pm
rna
Rating for RNA
Low
Report
Rating for RNA
10/27
12:40 pm
rna
Rating for RNA
Low
Report
Rating for RNA
10/27
12:35 pm
rna
Avidity Biosciences (NASDAQ:RNA) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $72.00 price target on the stock, up previously from $65.00.
Low
Report
Avidity Biosciences (NASDAQ:RNA) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $72.00 price target on the stock, up previously from $65.00.
10/27
12:19 pm
rna
Rating for RNA
Low
Report
Rating for RNA
10/27
11:21 am
rna
Rating for RNA
Low
Report
Rating for RNA
10/27
11:21 am
rna
Rating for RNA
Low
Report
Rating for RNA